搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
3 小时
on MSN
Receptor structure reveals novel drug design opportunities for Parkinson's disease
University of Southern California-led researchers have discovered the structural details of a brain receptor called GPR6, ...
Yahoo
2 天
Parkinson's Link to Gut Bacteria Suggests an Unexpected, Simple Treatment
Summary of findings from the study and speculations from previous research. (Nishiwaki et al., npj Parkinson's Disease, 2024) ...
5 天
on MSN
A Parkinson’s diagnosis at 38 changed her life — for the better
Two years ago, Sharon Chakkalackal of Toronto, Ont., was given a diagnosis she never expected — young-onset Parkinson’s ...
GEN
1 天
Gene and Cell Therapies Take Aim at Parkinson’s Disease
New therapies that are less intrusive but more lasting than current interventions promise to arrest and even reverse neurodegeneration.
12 天
on MSN
Brett Favre opens up about battle with Parkinson’s disease: ‘I feel like a board’
Brett Favre has opened up about living with Parkinson’s disease, saying he often wakes up feeling as stiff as “a board.” The ...
10 天
Former Newsnight host Jeremy Paxman credits his dog for Parkinson's disease diagnosis
The Movers and Shakers podcast host on how his Battersea rescue dog Derek the spaniel helped 'discover' his neurological ...
Business Insider
12 小时
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor ...
Pathogenic mutations in LRRK2 account for 4-5% of familial and 1-2% of sporadic Parkinson’s disease. 1,2 BIIB122 (DNL151) is a selective, central nervous system-penetrant small molecule inhibitor of ...
Labroots
8 天
Parkinson's Drug Causes Iron Deficiency, Disrupts Microbiome
Parkinson's drug, entacapone, induces iron deficiency, which alters the gut microbiome and triggers the growth of bacteria ...
2 天
Spur Therapeutics Announces Development Candidate in Parkinson’s Disease Gene Therapy Program
SPR301 is a potential best-in-class gene therapy candidate that delivers a more stable, rationally engineered version of GCase, the enzyme ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈